Scientists publish the first studies on the safety and effectiveness of inhaled vaccines
One dose of inhaled vaccine, equivalent to one fifth of an intramuscular dose, induces strong immunity. And after two inhalation doses, the titer of neutralizing antibodies reaches levels similar to those caused by an intramuscular dose.
Phase 1 study results, published in the internationally recognized journal The Lancet Infectious Diseases, show that the adenovirus-conjugated COVID-19 inhaled vaccine (Ad5-nCoV) was well tolerated and had a similar antibody response and cellular immunity.
Doctors of the Therapeutic Clinic of the Medical School of the Athens National University. The Kapodistrias of Theodora Psaltopoulou Panos Malandrakis, Yiannis Danasis and Thanos Dimopoulos (Rector of EKPA) summarize the relevant publication.
The analysis included 130 participants in one of five groups: intramuscular vaccination (one or two doses), inhalation vaccination (high or low dose, two doses), or both vaccines (initially one intramuscular dose and one inhaled booster dose). The primary safety point was the occurrence of side effects 7 days after vaccination.
In terms of immunity, the goal was to measure IgG antibodies to the spike protein of the SARS-CoV-2 virus. The most frequently reported side effects were fever, fatigue and headache, and they were more common in those who received the intramuscular vaccine.
The authors conclude that the inhaled Ad5-nCoV vaccine needs further research to confirm its safety and efficacy.